

Medicine summary -duloxetine (to end January 2009)

			Case Group	Death Outcomes	Sole
Case Count			49	0	42
Reaction Count	Cardiac disorders	Tachycardia	1	0	1
		Palpitations	3	0	3
Cardiac disorders		4	0	4	
Ear and labyrinth disorders	Ear and labyrinth disorders	Vertigo	1	0	1
		Ear and labyrinth disorders	1	0	1
Eye disorders	Eye disorders	Mydriasis	1	0	1
		Vision blurred	1	0	1
		Eye disorders	2	0	2
Gastrointestinal disorders	Gastrointestinal disorders	Reflux oesophagitis	1	0	1
		Diarrhoea	4	0	4
		Diarrhoea haemorrhagic	1	0	1
		Constipation	2	0	2
		Faeces discoloured	1	0	1
		Flatulence	1	0	1
		Abdominal pain	1	0	1
		Abdominal pain upper	2	0	2
		Abdominal discomfort	1	0	0
		Dysphagia	1	0	1
		Nausea	12	0	12
		Retching	1	0	1
		Vomiting	5	0	5
		Lip swelling	1	0	1
		Mouth ulceration	1	0	1
		Swollen tongue	3	0	2
		Gastrointestinal disorders	38	0	36
		General disorders and administration site conditions	General disorders and administration site conditions	Asthenia	1
Malaise	1			0	1
Gait disturbance	1			0	1
Oedema	1			0	1
Chest pain	1			0	1
Chest discomfort	1			0	1
Feeling abnormal	1			0	1
Feeling cold	1			0	0
Therapeutic product ineffective for unapproved indication	1			0	1
General disorders and administration site conditions	9			0	8
Hepatobiliary disorders	Hepatobiliary disorders	Hepatic function abnormal	1	0	1
		Hepatobiliary disorders	1	0	1
Injury, poisoning and procedural complications	Injury, poisoning and procedural complications	Drug exposure during pregnancy	1	0	1
		Injury, poisoning and procedural complications	1	0	1

Medicine summary -duloxetine (to end January 2009)

			Case Group	Death Outcomes	Sole
Reaction Count	Investigations	Blood pressure increased	1	0	1
		Weight increased	1	0	1
		Creatinine renal clearance decreased	1	0	0
		Investigations	3	0	2
	Metabolism and nutrition disorders	Hyponatraemia	3	0	3
		Dehydration	1	0	1
		Metabolism and nutrition disorders	4	0	4
	Musculoskeletal and connective tissue disorders	Arthralgia	1	0	0
		Myalgia	1	0	0
		Muscle tightness	1	0	0
		Trismus	1	0	0
		Musculoskeletal stiffness	1	0	1
		Neck pain	1	0	1
		Musculoskeletal and connective tissue disorders	6	0	2
		Nervous system disorders	Transient ischaemic attack	1	0
	Headache		5	0	4
	Migraine		2	0	1
	Disturbance in attention		1	0	1
	Dystonia		1	0	1
	Tremor		2	0	1
	Hyperreflexia		1	0	1
	Aphasia		1	0	1
	Lethargy		1	0	1
	Somnolence		2	0	1
	Syncope		1	0	1
	Dizziness		6	0	6
	Presyncope		1	0	1
	Paraesthesia		6	0	5
	Hypoaesthesia		1	0	1
	Serotonin syndrome		3	0	3
	Nervous system disorders		35	0	30
	Pregnancy, puerperium and perinatal conditions	Abortion spontaneous	1	0	1
		Pregnancy, puerperium and perinatal conditions	1	0	1
	Psychiatric disorders	Anxiety	1	0	1
		Nervousness	1	0	1
		Fear of death	1	0	1
		Bruxism	1	0	0
		Delirium	3	0	1
		Hallucination	1	0	1
		Mania	1	0	0

Medicine summary -duloxetine (to end January 2009)

			Case Group	Death Outcomes	Sole	
Reaction Count	Psychiatric disorders	Anger	2	0	2	
		Aggression	2	0	2	
		Homicidal ideation	1	0	1	
		Violence-related symptom	1	0	1	
		Anorgasmia	1	0	1	
		Insomnia	2	0	2	
		Intentional self-injury	2	0	2	
		Suicidal ideation	4	0	4	
		Psychiatric disorders	24	0	20	
	Renal and urinary disorders	Urinary hesitation	1	0	1	
		Urinary retention	1	0	1	
		Urine flow decreased	1	0	0	
		Renal and urinary disorders	3	0	2	
	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	1	0	1	
		Respiratory, thoracic and mediastinal disorders	1	0	1	
	Skin and subcutaneous tissue disorders	Dry skin	1	0	1	
		Pruritus	1	0	1	
		Rash pruritic	1	0	1	
		Rash macular	1	0	1	
		Hyperhidrosis	3	0	1	
		Skin and subcutaneous tissue disorders	7	0	5	
	Social circumstances	Sexual abuse	1	0	1	
		Social circumstances	1	0	1	
	Vascular disorders	Hypotension	1	0	1	
		Hypertension	2	0	2	
		Vascular disorders	3	0	3	
	Reaction			144	0	124